



Treating Severe Obesity

Metabolic & Bariatric Surgery

Bruce M. Wolfe, MD, FACS, FASMBS
Professor of Surgery
wolfeb@ohsu.edu

Definition of Severe Obesity

1991

BMI > 40, or

BMI > 35 with comorbidity

2017

BMI > 30, or less with
metabolic disease / T2DM

Comorbidity Remission

		<u>RYGB</u>	<u>LAGB</u>
<u>DM:</u>	Remission	61.9%	37.1%
	Incidence	0.9%	3.2%

<u>HTN:</u>	Remission	38.2%	17.4%
	Incidence	12.6%	18.0%

<u>Dyslipidemia:</u>	Remission	61.9%	27.1%
	Incidence	3.2%	16.0%

Courcoulas/LABS: JAMA. 2013; 310(22):2416.

LABS 1: Mortality

0.3%	All patients
0.2%	Laparoscopic gastric bypass
2.1%	Open gastric bypass
0%	Laparoscopic adjustable gastric banding

LABS 1: Serious Complications

4.1%	All patients
4.8%	Laparoscopic gastric bypass
7.8%	Open gastric bypass
1.0%	Laparoscopic adjustable gastric banding

Bariatric Surgery Safety Center Accreditation

Surgeon training, experience, laparoscopy

Data to central registry

Quality improvement

Standardized care protocols

Patient selection

Pre- and post-operative care

Roux-en-Y Gastric Bypass (RYGB)

Long-term Complications (1)

- Variable weight loss, comorbidity response
- Nutrient deficiency
 - Vitamin/mineral
 - Anemia
 - Central or peripheral neuropathy
 - Bone
- Metabolic
 - Hypoglycemia
 - Renal function, stones

Roux-en-Y Gastric Bypass (RYGB)

Long-term Complications (2)

- Surgical
 - Intestinal obstruction
 - Peptic ulcer
 - Abdominal pain
- Behavioral/psychological
 - Depression, suicide

Sociodemographic Predictors

c. Sex: Female versus male

Martin
OR: 2.59 (2.53, 2.63)

Korda
OR: 2.80 (2.16, 3.67)

Livingston
OR: 3.46 (3.32, 3.60)

Flum
OR: 2.29 (2.10, 2.51)


Padwal
OR: 2.80 (2.36, 3.35)

Mainous
OR: 2.69 (2.61, 2.75)

Poulose
OR: 3.82 (3.74, 3.90)

Birkmeyer
OR: 2.27 (2.16, 2.39)

Pooled Estimate
OR: 2.80 (2.46, 3.22)




Favours males

1

Favours females

Sociodemographic Predictors

b. Insurance: Privately insured versus not privately insured



LABS: Commercial vs Medicaid Payment

Commercial > Medicaid

White

Never smoker

BMI 47 vs 50 kg/m²

Diabetes 31% vs 40%

Walking limitation 3% to 26%

Access vs Actual Care

Actual Payment

High copays, specific requirements
Provider rejection

Information Gap

Health consequences of obesity
Patients, family, provider
Benefits vs risks of treatment

Metabolic/Bariatric Surgery: A Population Intervention?

Numbers could be increased


LOS sleeve 1.1 day, RYGB 2.1 days

Training programs

Identify patient populations who will benefit most

Less invasive procedures combined with medical therapy

Obesity v. Diabetes: Rates of Under-Treatment



Thomas: Obesity. 2016;24:1955-1961

Knowledge Gaps for Efficacy of Obesity Treatments

- Efficacy of drug and surgical treatments in racial/ethnic minority and other health disparities populations (low SES, rural, etc)
- Effectiveness of newer modes of delivery for lifestyle intervention in large and diverse populations
- Predictors of response, beyond initial weight loss for all obesity treatments
 - Genetic and phenotypic (including behavioral and metabolic) characteristics to allow more targeted treatment recommendations
- Long-term safety and efficacy of Sleeve Gastrectomy and other newer procedures and devices for obesity treatment, **combination therapy**
- **Identify best treatment for specific patients**